Current industrial practices of assessing permeability and P-glycoprotein interaction

被引:191
作者
Balimane, PV [1 ]
Han, YH [1 ]
Chong, SH [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA
关键词
permeability; high throughput; Caco-2; cells; transporters; drug discovery; PAMPA; P-gp;
D O I
10.1208/aapsj080101
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combination of the in vitro models that are high throughput but less predictive and the in vivo models that are low throughput but more predictive is used effectively to evaluate the intestinal permeability and transport characteristics of a large number of drug candidates during lead selection and lead optimization processes. Parallel artificial membrane permeability assay and Caco-2 cells are the most frequently used in vitro models to assess intestinal permeability. The popularity of these models stems from their potential for high throughput, cost effectiveness, and adequate predictability of absorption potential in humans. However, several caveats associated with these models (eg, poor predictability for transporter-mediated and paracellularly absorbed compounds, significant nonspecific binding to cells/devices leading to poor recovery, variability associated with experimental factors) need to be considered carefully to realize their full potential. P-glycoprotein, among other pharmaceutically relevant transporters, has been well demonstrated to be the major determinant of drug disposition. The review article presents an objective analysis of the permeability and transporter models currently being used in the pharmaceutical industry and could help guide the discovery scientists in implementing these models in an optimal fashion.
引用
收藏
页码:E1 / E13
页数:13
相关论文
共 52 条
[1]   Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[2]   Intestinal membrane transport of drugs and nutrients:: genomics of membrane transporters using expression microarrays [J].
Anderle, P ;
Huang, Y ;
Sadée, W .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :17-24
[3]   Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability [J].
Ano, R ;
Kimura, Y ;
Shima, M ;
Matsuno, R ;
Ueno, T ;
Akamatsu, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (01) :257-264
[4]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[5]  
ARTURSSON P, 1991, CRIT REV THER DRUG, V8, P305
[6]   The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds [J].
Aungst, BJ ;
Nguyen, NH ;
Bulgarelli, JP ;
Oates-Lenz, K .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1175-1180
[7]  
Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100
[8]   A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay [J].
Balimane, PV ;
Chong, SH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 301 (1-2) :80-88
[9]   Cell culture-based models for intestinal permeability: a critique [J].
Balimane, PV ;
Chong, S .
DRUG DISCOVERY TODAY, 2005, 10 (05) :335-343
[10]   Current methodologies used for evaluation of intestinal permeability and absorption [J].
Balimane, PV ;
Chong, SH ;
Morrison, RA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :301-312